{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T10:10:28Z","timestamp":1788689428680,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals SA","doi-asserted-by":"crossref","award":["VEO 000693"],"award-info":[{"award-number":["VEO 000693"]}],"id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Respiratory syncytial virus (RSV) is a major cause of acute respiratory infection (ARI) in adults aged\u2009\u2265\u200960 years, but data on its outpatient epidemiology and societal costs remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>BUCOSS was a prospective observational study conducted over 3 seasons (2022\/23\u20132024\/25) in adults aged\u2009\u2265\u200960 years presenting with ARI to 29 outpatient practices in Germany. Multiplex PCR testing was performed at baseline. RSV-positive patients were prospectively followed for up to 28 days. Clinical and socioeconomic burden, including direct medical, indirect, and patient-borne out-of-pocket costs, was assessed using structured questionnaires on days 0, 14, and 28. Approximate national burden was estimated using incidence-based and ARE\u2013prevalence-based extrapolation, including an additional scenario analysis excluding indirect costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 3,261 patients with ARI, 192 (5.9%) had PCR-confirmed RSV infection. RSV prevalence was 5.49%, and estimated RSV incidence was 1,030.6 cases per 100,000 population. After exclusion of 4 patients hospitalized at baseline, 188 patients were included in the outpatient cost analysis. Mean age was 71.6 (SD 8.52) years, 57.4% were female, and 60.1% met the study high-risk criteria. Mean societal cost per episode was \u20ac510.0 (SD \u20ac742.58); costs were highest in patients aged 60\u201364 years. Total costs comprised direct medical costs of \u20ac161.3 (SD \u20ac59.57), indirect costs of \u20ac331.8 (SD \u20ac746.75), and out-of-pocket costs of \u20ac16.9 (SD \u20ac22.25), corresponding to 31.6%, 65.1%, and 3.3% of total societal costs, respectively. Indirect costs were driven almost entirely by productivity losses. Approximately 40% of cases occurred in adults without study-defined high-risk status. The two extrapolation approaches yielded approximate estimates of 258,000\u2013374,000 medically attended outpatient RSV cases per season among adults aged\u2009\u2265\u200960 years in Germany, corresponding to \u20ac131.7\u2013190.9\u00a0million in societal costs. In a scenario analysis excluding indirect costs, the estimated burden decreased to \u20ac46.0\u201366.7\u00a0million per season.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>RSV is an economically important cause of outpatient ARI in older adults. These findings highlight a substantial outpatient burden beyond inpatient care and support RSV prevention strategies in aging populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12931-026-03866-1","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T01:04:54Z","timestamp":1786669494000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The outpatient economic burden of respiratory syncytial virus infection in adults aged\u2009\u2265\u200960 years in Germany: results from the BUCOSS study"],"prefix":"10.1186","volume":"27","author":[{"given":"Roland","family":"Diel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Alexander","family":"Hinze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grit","family":"Barten-Neiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Eberhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Knaupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alen","family":"Marijam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gernot","family":"Rohde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"issue":"11","key":"3866_CR1","doi-asserted-by":"publisher","first-page":"ofad513","DOI":"10.1093\/ofid\/ofad513","volume":"10","author":"A Njue","year":"2023","unstructured":"Njue A, Nuabor W, Lyall M, Margulis A, Mauskopf J, Curcio D, et al. Systematic literature review of risk factors for poor outcomes among adults with respiratory syncytial virus infection in high-income countries. Open Forum Infect Dis. 2023;10(11):ofad513.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"3866_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/cid\/ciy991","volume":"69","author":"B Ackerson","year":"2019","unstructured":"Ackerson B, Tseng HF, Sy LS, Solano Z, Slezak J, Luo Y, et al. Severe morbidity and mortality associated with respiratory syncytial virus versus influenza infection in hospitalized older adults. Clin Infect Dis. 2019;69(2):197\u2013203. https:\/\/doi.org\/10.1093\/cid\/ciy991.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"3866_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/QCO.0000000000001000","volume":"37","author":"S Kenmoe","year":"2024","unstructured":"Kenmoe S, Nair H. The disease burden of respiratory syncytial virus in older adults. Curr Opin Infect Dis. 2024;37(2):129\u201336. https:\/\/doi.org\/10.1097\/QCO.0000000000001000.","journal-title":"Curr Opin Infect Dis"},{"key":"3866_CR4","doi-asserted-by":"publisher","first-page":"105399","DOI":"10.1016\/j.jcv.2023.105399","volume":"161","author":"A Ambrosch","year":"2023","unstructured":"Ambrosch A, Luber D, Klawonn F, Kabesch M. Focusing on severe infections with respiratory syncytial virus in adults: risk factors, symptomatology, and clinical course compared to influenza A\/B and the original SARS-CoV-2 strain. J Clin Virol. 2023;161:105399. https:\/\/doi.org\/10.1016\/j.jcv.2023.105399. Erratum in: J Clin Virol. 2023;164:105443. https:\/\/doi.org\/10.1016\/j.jcv.2023.105443.","journal-title":"J Clin Virol"},{"issue":"8","key":"3866_CR5","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s40121-024-01006-0","volume":"13","author":"S Scholz","year":"2024","unstructured":"Scholz S, Dobrindt K, Tufts J, Adams S, Ghaswalla P, Ultsch B, et al. The burden of respiratory syncytial virus in Germany: a comprehensive data analysis suggests underdetection of hospitalizations and deaths in adults 60 years and older. Infect Dis Ther. 2024;13(8):1759\u201370. https:\/\/doi.org\/10.1007\/s40121-024-01006-0.","journal-title":"Infect Dis Ther"},{"issue":"5","key":"3866_CR6","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3390\/vaccines13050510","volume":"13","author":"F D\u2019Ambrosio","year":"2025","unstructured":"D\u2019Ambrosio F, Lomazzi M, Moore M, Maida A, Ricciardi R, Munno L, et al. Addressing the underestimated burden of RSV in older adults in Europe: epidemiology, surveillance gaps, and public health implications. Vaccines (Basel). 2025;13(5):510. https:\/\/doi.org\/10.3390\/vaccines13050510.","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"3866_CR7","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1080\/13696998.2024.2389676","volume":"27","author":"B Huebbe","year":"2024","unstructured":"Huebbe B, Mocek A, Manz KC, Vivirito A, Bayer LJ, Norris R, et al. Economic burden of respiratory syncytial virus in adults in Germany: a health claims analysis between 2015 and 2018. J Med Econ. 2024;27(1):1063\u201375. https:\/\/doi.org\/10.1080\/13696998.2024.2389676.","journal-title":"J Med Econ"},{"issue":"3","key":"3866_CR8","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s41669-025-00565-3","volume":"9","author":"P Marijic","year":"2025","unstructured":"Marijic P, Kliemt R, Krammer M, Kolb N, Last T, Ambrosch A, et al. Costs and complications of respiratory syncytial virus and acute respiratory infections in the adult population: analysis of a German claims database. Pharmacoecon Open. 2025;9(3):445\u201359. https:\/\/doi.org\/10.1007\/s41669-025-00565-3.","journal-title":"Pharmacoecon Open"},{"key":"3866_CR9","unstructured":"Eurostat. Employment and activity by sex and age-annual data (lfsi_emp_a). Luxembourg: European Commission; 2024. Available at: https:\/\/ec.europa.eu\/eurostat\/databrowser\/product\/view\/LFSI_EMP_A?lang=en. Cited 31 Mar 2026."},{"issue":"7","key":"3866_CR10","doi-asserted-by":"publisher","first-page":"e102586","DOI":"10.1371\/journal.pone.0102586","volume":"9","author":"DL McClure","year":"2014","unstructured":"McClure DL, Kieke BA, Sundaram ME, Simpson MD, Meece JK, Sifakis F, et al. Seasonal incidence of medically attended respiratory syncytial virus infection in a community cohort of adults\u2009\u2265\u200950 years old. PLoS ONE. 2014;9(7):e102586. https:\/\/doi.org\/10.1371\/journal.pone.0102586.","journal-title":"PLoS ONE"},{"issue":"4","key":"3866_CR11","doi-asserted-by":"publisher","first-page":"2002688","DOI":"10.1183\/13993003.02688-2020","volume":"57","author":"K Korsten","year":"2021","unstructured":"Korsten K, Adriaenssens N, Coenen S, Butler C, Ravanfar B, Rutter H, et al. Burden of respiratory syncytial virus infection in community-dwelling older adults in Europe (RESCEU): an international prospective cohort study. Eur Respir J. 2021;57(4):2002688. https:\/\/doi.org\/10.1183\/13993003.02688-2020.","journal-title":"Eur Respir J"},{"key":"3866_CR12","unstructured":"Kassen\u00e4rztliche Bundesvereinigung. Einheitlicher Bewertungsma\u00dfstab (EBM) [Uniform Value Scale (EBM)]. Berlin: Kassen\u00e4rztliche Bundesvereinigung. Available at: https:\/\/www.kbv.de\/praxis\/abrechnung\/ebm. Cited 31 Mar 2026."},{"key":"3866_CR13","unstructured":"Bundesministerium f\u00fcr Gesundheit. Zuzahlung und Erstattung von Arzneimitteln [Copayments and reimbursement of medicinal products]. Berlin: Bundesministerium f\u00fcr Gesundheit. Available at: https:\/\/www.bundesgesundheitsministerium.de\/zuzahlung-und-erstattung-arzneimittel. Cited 31 Mar 2026."},{"key":"3866_CR14","unstructured":"Bundesministerium der Finanzen. Lohnsteuer-Hinweise 2025: Pauschale Kilometers\u00e4tze [Wage Tax Guidelines 2025: Flat-rate mileage allowances]. Berlin: Bundesministerium der Finanzen; 2025. Available at: https:\/\/lsth.bundesfinanzministerium.de\/lsth\/2025\/A-Einkommensteuergesetz\/II-Einkommen-2-24b\/4-Ueberschuss-d-Einnahmen-ueber-die-Werbungsk-8-9a\/Paragraf-9\/h-9-5.html. Cited 31 Mar 2026."},{"issue":"4","key":"3866_CR15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2165\/00019053-200826040-00001","volume":"26","author":"MA Koopmanschap","year":"2008","unstructured":"Koopmanschap MA, van Exel JN, van den Berg B, Brouwer WB. An overview of methods and applications to value informal care in economic evaluations of healthcare. PharmacoEconomics. 2008;26(4):269\u201380. https:\/\/doi.org\/10.2165\/00019053-200826040-00001.","journal-title":"PharmacoEconomics"},{"issue":"4","key":"3866_CR16","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.socscimed.2005.06.046","volume":"62","author":"B van den Berg","year":"2006","unstructured":"van den Berg B, Brouwer W, van Exel J, Koopmanschap M, van den Bos GA, Rutten F. Economic valuation of informal care: lessons from the application of the opportunity costs and proxy good methods. Soc Sci Med. 2006;62(4):835\u201345. https:\/\/doi.org\/10.1016\/j.socscimed.2005.06.046.","journal-title":"Soc Sci Med"},{"key":"3866_CR17","unstructured":"Statistisches Bundesamt (Destatis). Inlandsproduktsberechnung-Detaillierte Jahresergebnisse (endg\u00fcltige Ergebnisse), Fachserie 18 Reihe 1.4 [National accounts-Detailed annual results (final results), Series 18, Row 1.4]. Wiesbaden: Statistisches Bundesamt. 2025. Available at: https:\/\/www.destatis.de\/DE\/Themen\/Wirtschaft\/Volkswirtschaftliche-Gesamtrechnungen-Inlandsprodukt\/Publikationen\/Downloads-Inlandsprodukt\/inlandsprodukt-endgueltig-xlsx-2180140.html. Cited 31 Mar 2026."},{"issue":"4","key":"3866_CR18","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1524-4733.2007.00301.x","volume":"11","author":"JM von der Graf","year":"2008","unstructured":"von der Graf JM, Greiner W, Jost F, Klusen N, Kubin M, Leidl R, et al. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Value Health. 2008;11(4):539\u201344. https:\/\/doi.org\/10.1111\/j.1524-4733.2007.00301.x.","journal-title":"Value Health"},{"key":"3866_CR19","unstructured":"Statistikportal, Arbeitnehmerentgelt. Bruttol\u00f6hne und -geh\u00e4lter in den L\u00e4ndern der Bundesrepublik Deutschland 1991 bis 2024 [Compensation of employees and gross wages and salaries in the federal states of Germany, 1991 to 2024]. D\u00fcsseldorf: Statistikportal; 2025. Available at: https:\/\/www.statistikportal.de\/de\/veroeffentlichungen\/arbeitnehmerentgelt-bruttoloehne-und-gehaelter. Cited 31 Mar 2026."},{"key":"3866_CR20","unstructured":"Minijob-Zentrale. Mindestlohn im Minijob [Minimum wage in mini-jobs]. Essen: Minijob-Zentrale. Available at: https:\/\/www.minijob-zentrale.de\/DE\/die-minijobs\/arbeitsrechte-im-minijob\/mindestlohn. Cited 31 Mar 2026."},{"key":"3866_CR21","unstructured":"Statistisches Bundesamt (Destatis). GENESIS-Online Datenbank, Tabelle 12411-0005: Bev\u00f6lkerung: Deutschland, Stichtag, Altersjahre [GENESIS-Online database, table 12411-0005: Population: Germany by reference date and age in years]. Wiesbaden: Statistisches Bundesamt. Available at: https:\/\/www-genesis.destatis.de\/genesis\/online. Cited 31 Mar 2026."},{"issue":"10","key":"3866_CR22","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2217\/fvl-2023-0069","volume":"18","author":"A Igarashi","year":"2023","unstructured":"Igarashi A, Togo K, Kobayashi Y, Kamei K, Yonemoto N, Ishiwada N. Inpatient and outpatient costs associated with respiratory syncytial virus in Japanese infants and older adults. Future Virol. 2023;18(10):643\u201357. https:\/\/doi.org\/10.2217\/fvl-2023-0069.","journal-title":"Future Virol"},{"issue":"Suppl 1","key":"3866_CR23","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1093\/infdis\/jiac069","volume":"226","author":"Z Mao","year":"2022","unstructured":"Mao Z, Li X, Korsten K, Bont L, Butler C, Wildenbeest J, et al. Economic burden and health-related quality of life of respiratory syncytial virus and influenza infection in European community-dwelling older adults. J Infect Dis. 2022;226(Suppl 1):S87\u201394. https:\/\/doi.org\/10.1093\/infdis\/jiac069.","journal-title":"J Infect Dis"},{"issue":"10","key":"3866_CR24","doi-asserted-by":"publisher","first-page":"e70174","DOI":"10.1111\/irv.70174","volume":"19","author":"SF Hak","year":"2025","unstructured":"Hak SF, Wildenbeest JG, Bracaloni S, Scarpaci M, Cosci T, Esposito E, et al. Clinical and socioeconomic burden of RSV infections among older adults in primary care: an international prospective cohort study. Influenza Other Respir Viruses. 2025;19(10):e70174. https:\/\/doi.org\/10.1111\/irv.70174.","journal-title":"Influenza Other Respir Viruses"},{"issue":"3","key":"3866_CR25","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1128\/CMR.13.3.371","volume":"13","author":"AR Falsey","year":"2000","unstructured":"Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev. 2000;13(3):371\u201384. https:\/\/doi.org\/10.1128\/CMR.13.3.371.","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"3866_CR26","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1378\/chest.11-0047","volume":"140","author":"FEH Lee","year":"2011","unstructured":"Lee FEH, Walsh EE, Falsey AR. The effect of steroid use in hospitalized adults with respiratory syncytial virus-related illness. Chest. 2011;140(5):1155\u201361. https:\/\/doi.org\/10.1378\/chest.11-0047.","journal-title":"Chest"},{"issue":"8","key":"3866_CR27","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1093\/cid\/cit471","volume":"57","author":"N Lee","year":"2013","unstructured":"Lee N, Lui GCY, Wong KT, Li TCM, Tse ECM, Chan JYC, et al. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin Infect Dis. 2013;57(8):1069\u201377. https:\/\/doi.org\/10.1093\/cid\/cit471.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"3866_CR28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jointm.2024.03.001","volume":"4","author":"Y Pe\u00f1a-L\u00f3pez","year":"2024","unstructured":"Pe\u00f1a-L\u00f3pez Y, Sabater-Riera J, Raj P. Severe respiratory syncytial virus disease. J Intensive Med. 2024;4(4):405\u201316. https:\/\/doi.org\/10.1016\/j.jointm.2024.03.001.","journal-title":"J Intensive Med"},{"issue":"7","key":"3866_CR29","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2209604","volume":"388","author":"A Papi","year":"2023","unstructured":"Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, et al. Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med. 2023;388(7):595\u2013608. https:\/\/doi.org\/10.1056\/NEJMoa2209604.","journal-title":"N Engl J Med"},{"issue":"16","key":"3866_CR30","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","volume":"388","author":"EE Walsh","year":"2023","unstructured":"Walsh EE, P\u00e9rez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M, et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med. 2023;388(16):1465\u201377. https:\/\/doi.org\/10.1056\/NEJMoa2213836.","journal-title":"N Engl J Med"},{"issue":"5","key":"3866_CR31","doi-asserted-by":"publisher","first-page":"e258322","DOI":"10.1001\/jamanetworkopen.2025.8322","volume":"8","author":"SE Fry","year":"2025","unstructured":"Fry SE, Terebuh P, Kaelber DC, Xu R, Davis PB. Effectiveness and safety of respiratory syncytial virus vaccine for US adults aged 60 years or older. JAMA Netw Open. 2025;8(5):e258322. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.8322.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"3866_CR32","doi-asserted-by":"publisher","first-page":"2641671","DOI":"10.1080\/14760584.2026.2641671","volume":"25","author":"MJ Fonseca","year":"2026","unstructured":"Fonseca MJ, Bratkovi\u0107 S, \u00c7olak Y, Helleberg M, Vestbo J, Burns S, et al. Adjuvanted-RSVPreF3 vaccine uptake and effectiveness in individuals with COPD: a nationwide Danish cohort study. Expert Rev Vaccines. 2026;25(1):2641671. https:\/\/doi.org\/10.1080\/14760584.2026.2641671.","journal-title":"Expert Rev Vaccines"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-026-03866-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03866-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03866-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T09:57:24Z","timestamp":1788688644000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12931-026-03866-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3866"],"URL":"https:\/\/doi.org\/10.1186\/s12931-026-03866-1","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"28 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. This clinical study was approved by the Ethics Committee of Goethe University Frankfurt am Main (approval number: 2022\u2009\u2212\u2009907). All participants provided written informed consent prior to enrollment.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CW declares honoraria for lectures, presentations or educational events from Abbvie, Gilead, ViiV Healthcare, Pfizer and MSD and payment for participation in advisory boards for Abbvie, Gilead, ViiV Healthcare, Pfizer, and MSD. RR and AM are employees and hold shares of GSK. GR reports personal fees from Astra Zeneca, Atriva, Boehringer Ingelheim, GSK, Insmed, MSD, Sanofi, Novartis and Pfizer for consultancy during advisory board meetings and personal fees from Astra Zeneca, Berlin Chemie, BMS, Boehringer Ingelheim, Chiesi, Essex Pharma, Grifols, GSK, Insmed, J&J, MSD, Roche, Sanofi, Solvay, Takeda, Novartis, Pfizer and Vertex for lectures. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"344"}}